Insulin-like growth factor-binding protein 7 (IGFBP7) is a secreted protein involved in several cellular processes, including proliferation, senescence and apoptosis. Loss of IGFBP7 expression is a critical step in the development of human tumors, including melanoma and colon cancer. By microarray gene expression studies, we have detected downregulation of IGFBP7 gene expression in follicular and papillary thyroid tumors in comparison with normal thyroid tissue. Evaluation of publicly available PTC microarray gene expression data sets confirmed, in a consistent fraction of tumors, the downregulation of IGFBP7 transcript levels. The functional consequence of IGFBP7 downregulation was addressed in the PTCderived NIM1 cell line in which IGFBP7 expression is repressed by promoter hypermethylation. Exposure to soluble IGFBP7 protein or restoration of IGFBP7 expression by complementary DNA transfection reduced growth rate, migration, anchorage-independent growth and tumorigenicity of NIM1 cells. We show that the effects of IGFBP7 are related to apoptosis. Our data suggest that loss of IGFBP7 expression has a functional role in thyroid carcinogenesis, and it may represent a possible basis for therapeutic strategies.
Introduction
Thyroid cancer is the most frequent endocrine neoplasia and its incidence has increased significantly during the past decades (Davies and Welch, 2006) . The majority of thyroid tumors originate from the thyroid epithelial follicular cells and includes benign adenomas, welldifferentiated, indolent papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), as well as extremely aggressive anaplastic thyroid carcinoma.
Many genes involved in thyroid carcinogenesis have been discovered, and the delineation of the pathways through which they act has been characterized (Greco et al., 2009) . FTC is associated with the PAX8/PPARg rearrangement and activating mutations of RAS genes. PTC, which accounts for approximately 80% of all primary thyroid cancers, is characterized by rearrangements involving the RET and NTRK1 tyrosine kinase receptors, and by the V600E BRAF-activating mutation. Recent advances in molecular technologies have allowed evaluating the expression levels of thousands of genes in thyroid tumors.
Gene expression analysis studies have identified several genes, involved in different cellular processes, which might be important in the molecular pathogenesis and the malignant progression of thyroid cancer (Huang et al., 2001; Giordano et al., 2005) . Differences between gene expression profiles of PTC and normal thyroid have suggested the applicability of gene expression findings to diagnosis purposes (Jarzab et al., 2005) ; a combination of five genes was suggested to distinguish PTC from FTC (Aldred et al., 2004) . In spite of the numerous gene expression studies, validated by different approaches, only a few data addressing the role of differentially expressed genes in the pathogenesis of thyroid tumors have been produced yet (Ferrario et al., 2008; Latini et al., 2008; Pallante et al., 2008) . Nevertheless, such studies are important for a deeper understanding of molecular mechanisms underlying thyroid carcinogenesis, and they could also identify possible new strategies for therapeutic intervention.
Insulin-like growth factor-binding protein 7 (IGFBP7), also called IGFBP-rP1 or MAC25, is a member of the IGFBP superfamily, including 16 secreted proteins binding IGFs with variable affinity (Burger et al., 2005) . IGFBP7 binds IGFs with low affinity, but in contrast, recognizes insulin with high affinity, and thereby modifies its metabolism, distribution and ability to bind to the insulin receptor (Yamanaka et al., 1997) . IGFBP7 has also IGF/ insulin-independent actions. A large body of evidence suggests that IGFBP7 functions as an oncosuppressor gene in human prostate, breast, lung and colorectal cancer, as it regulates cell proliferation, cell adhesion, cellular senescence and angiogenesis (Akaogi et al., 1996; Sprenger et al., 1999; Wilson et al., 2002; Burger et al., 2005; Ruan et al., 2006; Chen et al., 2007; Sato et al., 2007) . IGFBP7 is silenced by promoter hypermethylation in several neoplastic tissues, including colorectal and gastric cancers (Kanemitsu et al., 2000; Ahmed et al., 2003; Lin et al., 2007) . More recently, IGFBP7 has been shown to mediate senescence in melanocytes, and to suppress melanoma growth in vivo by inducing apoptosis (Wajapeyee et al., 2008) . Studies in mouse models have suggested IGFBP7 as a therapeutic agent for treatment of metastatic melanoma and colorectal tumors carrying RAS or BRAF mutations (Wajapeyee et al., 2009) .
In this study, we investigate the role of IGFBP7 in PTC. Analysis of expression levels in microarray data sets highlighted that IGFBP7 was downregulated in a consistent fraction of PTC, with respect to normal thyroid. To address the functional consequences of IGFBP7 downregulation we used the PTC-derived NIM1 cell line, in which the expression of IGFBP7 is lacking. Exposure to soluble IGFBP7 protein or restoration of IGFBP7 expression by complementary DNA (cDNA) transfection reduced growth rate, migration, anchorage-independent growth and tumorigenicity of NIM1 cells. We provide evidence that the effects of IGFBP7 are related to apoptosis. Overall, our data suggest that IGFBP7 gene exerts an oncosuppressor role in thyroid epithelial carcinogenesis.
Results

Expression of IGFBP7 in PTC
To examine the biological relevance of IGFBP7 in papillary thyroid carcinogenesis, its expression level in normal thyroid tissues or thyroid carcinomas was first analyzed on cDNA microarray data produced in our laboratory (Ferrario et al., 2008) . As shown in Figure 1a , in comparison with IGFBP7 gene expression level in normal thyroid (9 samples), IGFBP7 transcripts were significantly downregulated in both FTC (11 samples) and PTC (31 samples) histotypes with a P-value o0.05. Downregulation of IGFBP7 affected a consistent fraction of PTC cases, with 16 out of 31, including 80% of tall cell (TC) variants, showing expression levels lower than the lowest level of normal samples. To further analyze the role of IGFBP7 in PTC we used three independent, publicly available data sets of microarray gene expression data of thyroid PTC samples, all obtained using Affymetrix HG-U133 series platforms (Affymetrix, Santa Clara, CA, USA). In the He data set (He et al., 2005) , PTC showed a reduced IGFBP7 expression when compared with unaffected thyroid tissues from the same patients in five out of nine cases with both probe sets (201162_at and 201163_at) but did not reach statistical significance (data not shown). In the Giordano data set (Giordano et al., 2005) significantly reduced expression of IGFBP7 (Po0.05) was observed in the TC variants (10 TC out of 26 total PTC) when compared with normal thyroid with one of the two probesets (201162_at, data not shown). Even for the second probe set, however, 40% of TC variants showed hybridization values lower than the lowest level of normal samples. In the Vasko data set (Vasko et al., 2007) , which included normal thyroid and microscopically dissected intratumoral samples of PTC from four patients, both central and invasive regions showed reduced expression of IGFBP7 transcripts (Po0.01) with both 201162_at and 201163_at probe sets, in comparison with the normal region (Figure 1b) . Overall, these results suggest that expression of IGFBP7 is downregulated in a consistent fraction of PTC with respect to normal thyroid.
Expression analysis of IGFBP7 in thyroid tumor cell lines
To further examine the role of IGFBP7 in thyroid carcinogenesis, we analyzed its expression in several thyroid tumor cell lines, including PTC-derived (TPC1, NIM1, BCPAP and K1) and anaplastic thyroid carcinoma-derived (BHT and KAT4) cell lines. Except for TPC1, which carries the RET/PTC1 oncogene, all the other cell lines harbor the BRAFV600E mutation. As control the melanoma SKMEL-31 cell line, known to express IGFBP7, was used (Wajapeyee et al., 2008) . As IGFBP7 is a secreted protein, its presence in the conditioned medium (CM) was analyzed. For each cell line, an aliquot of CM corresponding to 4 Â 10 5 cells was analyzed by western blot with anti-IGFBP7 antibodies. Expression of IGFBP7 protein was strong in BCPAP, K1 and BHT cell lines, reduced in TPC1 and KAT4, and undetectable in NIM1 cell line (Figure 2a ). The lack of expression of IGFBP7 in NIM1 cells was due to absence of the relative mRNA, as shown by reverse transcriptase-PCR (Figure 2b) . Treatment with the demethylating agent 5-aza-2'deoxycitidine (5-Aza-dC) restored the IGFBP7 mRNA expression, indicating that the lack of IGFBP7 protein in NIM1 cells is caused by promoter DNA hypermethylation.
IGFBP7 reduces NIM1 cells growth rate
To analyze the potential pathogenic role of IGFBP7 in PTC, we produced an in vitro model of thyroid cancer based on the restoration of the IGFBP7 expression in NIM1 cells. The latter, derived from a PTC, harbor the BRAFV600E mutation (our unpublished results) and are tumorigenic in nude mice (Zeki et al., 1993) . As first approach, we determined the growth rate of NIM1 cells exposed to CM from K1 cell line, expressing IGFBP7 (Figure 2a ), or to their own CM. The experiment reported in Figure 3a shows that growth rate of NIM1 cells exposed to IGFBP7-containing medium is reduced with respect to control. The reduction was evident at day 2, and accounted for 47% at day 4. To verify whether the inhibitory effect of the K1 CM is due to the presence of IGFBP7, we performed an immunodepletion with anti-IGFBP7 antibodies. Although the immunodepletion did not remove completely IGFBP7 from K1 CM (Figure 3a , inset), we observed a partial restoration of the NIM1 cells growth.
We next analyzed the effect of restoration of IGFBP7 expression in NIM1 cells by cDNA transfection. To this end, NIM1 cells were transfected with a plasmid expression vector containing the IGFBP7 cDNA in frame with myc epitope or the empty vector, and selected in G418. NIM1 cells transfected with IGFBP7 expression vector produced G418-resistant colonies smaller than those obtained with the empty vector (Figure 3b ), supporting the notion that IGFBP7 protein negatively regulates NIM1 growth rate. Several NIM1-IGFBP7 clones were isolated and analyzed; in 6 out of 12 the expression of the IGFBP7 protein was detected at variable levels in the CM (Figure 3c ). The growth rate of three clones expressing different level of IGFBP7, namely NIM1-I2, NIM1-I11 and NIM1-I13 was determined ( Figure 3d ). For all the clones a growth decrease with respect to parental NIM1 cells was observed, and such decrease correlated with the expression level of IGFBP7 protein. In fact at day 5, growth rate was reduced of 39% for NIM1-I11, of 59% for NIM1-I13 and of 66% for NIM1-I2. Overall, these data show that IGFBP7 negatively regulates growth of thyroid tumor cells.
IGFBP7 reduces anchorage-independent growth and migration of NIM1 cells
Tumor cells show the capability to grow in the absence of adhesion. We analyzed whether this feature in NIM1 cells is affected by IGFBP7 by performing soft agar assay. For these experiments we used clones NIM1-I2, NIM1-I5 and NIM1-I13, all producing high but variable levels of IGFBP7 protein ( Figure 3c ); as control, the NIM1-EV clone, transfected with empty vector, was used. As shown in Figure 4 , NIM1-IGFBP7 clones formed colonies with efficiency reduced with respect to the control; reduction accounted to 82% for NIM1-I2, 67% for NIM1-I5 and 75% for NIM1-I13. In addition, the colonies formed by NIM1-IGFBP7 clones were smaller than those formed by the control cells.
We next analyzed the migration capability of NIM1-IGFBP7 clones by the wound healing assay; as control, the NIM1-EV clone was used. The wound healing was monitored between 4 and 24 h, and the wound closure rate was calculated 4 and 8 h after scratching ( Figure 5 ). All the NIM1-IGFBP7 clones showed reduced wound healing capability with respect to empty vector-transfected NIM1 cells. Such reduction ranged from 30 to 35% 4 h after scratching, and from 31 to 51% 8 h after scratching. The wound of control cells was completely healed after 8 h ( Figure 5 ), whereas for NIM1-IGFBP7 clones the scratch was not yet closed within 24 h (data not shown).
IGFBP7 reduces tumorigenicity of NIM1 cells
To analyze whether re-expression of IGFBP7 could affect the in vivo growth of NIM1 cells, NIM1-IGFBP7 clones and NIM1 cells were injected into nude mice (Table 1) . In mice injected with 2 Â 10 6 cells, tumor growth was observed in 3/3 mice injected with NIM1 cells, whereas no tumor growth occurred in those injected with NIM1-IGFBP7 clones. When 5 Â 10 6 cells were injected, no take was observed in mice xenografted with NIM1-I2 cells. In mice injected with NIM-I5 and NIM1-I13 cells, 3/3 takes were observed, but regression occurred in 1/3 animal for each clone; in the remaining animals tumors grew slower than NIM1 tumors.
IGFBP7 impairs cell cycle progression and modulates ERK activation p21 and p53 expression To examine the mechanisms by which IGFBP7 negatively regulates the growth of NIM1 cells, we performed cell cycle phase distribution of transiently transfected NIM1 cells through flow cytometric analysis. As shown in Figure 6a , re-expression of IGFBP7 in NIM1 cells increased the percentage of cells in G1 (84%) compared with the empty vector-transfected NIM1 cells (65%) with a consequent decrease of the percentage of cells in S phase (8% in NIM1-IGFBP7 versus 24% in control) as evaluated by DNA content analysis (Figure 6a ). The G1 arrest caused by IGFBP7 was associated with a strong decline of phospho-ERK levels and an upregulation of p53 and p21 tumor suppressors (Figure 6b ). IGFBP7-transfected NIM1 cells compared with the control showed 70% reduction of phospho-ERK levels, and an increase of p53 and p21 expression of 49% and of 54%, respectively, as assessed by densitometric analysis (Figure 6b ). a NIM1-IGFBP7 clones and parental NIM1 cells were inoculated subcutaneously into the left flank of athymic nude mice as described in Materials and methods section. Tumor growth was monitored twice a week from day 8 to day 60.
IGFBP7 and thyroid cancer MG Vizioli et al IGFBP7 mediates cell growth suppression through induction of apoptosis We analyzed whether the effects induced by IGFBP7 in NIM1 cells could be related to apoptosis. To this end, we analyzed the capacity of IGFBP7 to induce apoptosis, alone or in combination with TRAIL, a proapoptotic agent effective in NIM1 cells (our unpublished results), by determining the levels of cleaved PARP. We observed that IGFBP7 transiently transfected NIM1 cells showed higher levels of cleaved PARP compared with empty vector-transfected cells (Figure 7a ). Exposure to TRAIL (50 ng/ml for 5 h) generated a higher induction of apoptosis in IGFBP7-transfected NIM1 cells with respect to the control (Figure 7a ), suggesting that IGFBP7 may cooperate with other stimuli in inducing apoptosis. These observations were also confirmed by analyzing the levels of cleaved PARP in NIM1-IGFBP7 clones (Figure 7b ). In clone NIM1-I2, expressing the highest amount of IGFBP7 protein (Figure 3c ), cleaved PARP was observed in untreated cells, and it was strongly induced by TRAIL treatment. Clones NIM1-I5 and NIM1-I13, both expressing lower amount of IGFBP7 protein with respect to NIM1-I2, showed low levels of cleaved PARP, which increased after TRAIL exposure. In the control cells, cleaved PARP was detectable after TRAIL treatment, but to a lesser extent with respect to NIM1-I5 and NIM1-I13 in the presence of TRAIL.
Discussion
We have shown that IGFBP7 protein exerts a negative regulation on thyroid tumor cells. By analysis of gene expression data produced in our laboratory, we have detected significant reduction of IGFBP7 gene expression in both FTC and PTC. Downregulation of IGFBP7 gene in PTC compared with normal thyroid was also observed in different, publicly available gene expression data sets. This in silico analysis even indicated that IGFBP7 downregulation is associated with the TC variant of PTC. Silencing of IGFBP7 gene in melanoma was originally found associated with the BRAFV600E mutation (Wajapeyee et al., 2008) . However, such correlation was not confirmed by subsequent studies showing loss of IGFBP7 expression regardless of BRAF status (Wajapeyee et al., 2009; Schrama et al., 2010) . In colorectal cancer, loss of IGFBP7 has been associated with BRAFV600E mutation by two different studies (Hinoue et analysis indicates the absence of correlation between loss of IGFBP7 and BRAFV600E mutation in thyroid carcinoma. In keeping with this, among five cell lines carrying the BRAFV600E mutation, only two showed downregulation of IGFBP7 expression.
To determine whether IGFBP7 contributes to thyroid carcinogenesis we used the NIM1 cell line, derived from a PTC carrying the BRAFV600E mutation, in which the expression of IGFBP7 gene is abrogated by promoter hypermethylation. Several lines of evidence suggest that restoration of IGFBP7 in NIM1 cells interferes with cell growth. Reduction of growth rate was in fact detected in NIM1 cells exposed to soluble IGFBP7 and in clones obtained by stable transfection with an IGFBP7 expression vector. We also provided evidence that IGFBP7 interferes with other tumor cell properties, such as anchorage-independent growth and migration capability: both of them were reduced in NIM1 clones stably expressing the IGFBP7 protein. In vivo experiments have shown that restoration of IGFBP7 expression reduces the NIM1 cells capability to induce tumor formation in mouse xenografts.
IGFBP7 negatively regulates NIM1 cell growth by triggering apoptosis. Concomitantly to growth inhibition and attenuation of ERKs signalling, we observed upregulation of p53 and p21, which led to G1 arrest and apoptosis in IGFBP7-expressing NIM1 cells. Altogether our data suggest IGFBP7 as a tumor suppressor in thyroid carcinogenesis.
Oncogene-induced senescence has been recently suggested as a potent barrier to tumorigenesis being present in premalignant lesions, whereas malignant tumors have acquired the capability to escape it. IGFBP7 has been identified as a mediator of oncogene-induced senescence in benign nevi. Loss of IGFBP7 expression accounts for uncontrolled proliferation of melanoma; addition of IGFBP7 to melanoma cells inhibits ERK signalling and activates apoptosis (Wajapeyee et al., 2008) . The capacity of IGFBP7 to induce apoptosis has been also shown in cell lines derived from different tumor types, such as colorectal, prostate and lung (Sprenger et al., 1999; Chen et al., 2007; Ruan et al., 2007) . More recently, IGFBP7 has been suggested as an efficacious agent for treating malignancies that are dependent on BRAF-MEK-ERK signalling (Wajapeyee et al., 2009) .
Our study provides evidence that apoptosis is also involved in the suppressor effects of IGFBP7 in thyroid tumor cells. In our experimental system, IGFBP7 was capable to induce apoptosis and to potentiate the apoptotic effect of TRAIL. The capacity of IGFBP7 to induce senescence in primary cells and apoptosis in tumor cells supports the notion that cancer cells that have bypassed senescence are in general more susceptible to apoptosis (Lowe et al., 2004) .
The molecular events underlying thyroid cancer initiation and progression have been in part elucidated. Nevertheless, a role for tumor suppressor genes in thyroid carcinogenesis has not been assessed yet. Several recent studies highlight the power of gene expression analysis as a tool for the identification, among others, of putative oncosuppressor genes. In the last few years, in fact, some genes identified as downregulated in the contest of gene expression studies, were classified as tumor suppressors by functional studies, as their reexpression modulated transformed properties of thyroid carcinoma cell lines. Restoration of MT1G (Ferrario et al., 2008) , CBX7 (Pallante et al., 2008) , ABI3BP (Latini et al., 2008) , TIMP3 genes (our unpublished results) or IGFBP7 (this study) in thyroid tumor cell lines lacking their expression affected cell growth and transformed properties. The downregulation of IGFBP7 gene expression in PTC raises the attractive hypothesis that oncogeneinduced senescence might represent a relevant mechanism in thyroid carcinogenesis. This hypothesis is also supported by the frequent activation of the BRAF-MEK-ERK pathway, through BRAFV600E, PTC/RET or TRK oncogenes. Further studies are required to assess whether bypass of senescence may be an important step in thyroid cancer, and its possible utility for therapeutic intervention.
Materials and methods
Microarray data sets and statistical analysis
The expression of IGFBP7 was examined on microarray data sets containing normal thyroid tissues and PTC. One data set, generated in our laboratory from cDNA microarray hybridization, contains the expression profile data of 45 thyroid samples collected at the Department of Pathology of our institute. Sample collection includes: 9 normal thyroid tissues, 11 FTC and 34 PTC. The PTC collection (24 classical types and 10 TC variants) consists of cases carrying BRAFV600E mutation (12 samples), RET/PTC rearrangements (7 samples), TRK rearrangements (2 samples), none of the above genetic lesions (13 samples). The details of gene expression analysis have been previously reported (Ferrario et al., 2008) . The other data sets are publicly available and all derived from experiments using HG-U133 series microarrays (Affymetrix). These data sets contained data obtained from: (a) 51 PTC samples (including 26 classical types, 15 follicular variants, 10 TC variants) and 4 normal thyroid tissues (Giordano et al., 2005) ; among PTC samples, 25 carry the BRAFV600E mutation, 6 RAS mutations, 1 RET/PTC rearrangement; 19 samples none of the above genetic lesions; (b) paired PTC and unaffected thyroid tissue samples from nine patients (He et al., 2005) ; (c) paired central and invasive region of PTC and normal tissue from four patients (Vasko et al., 2007) . RMA normalized data were extracted from the NCBI Gene Expression Omnibus database (GSE3467 for the He data set and GSE6004 for the Vasko data set) or from the author's website (Giordano data set). All IGFBP7 probe sets were considered for expression analysis. Statistical analysis and graphs were generated using GraphPad Prism version 5.0 (San Diego, CA, USA). Comparison between two groups was performed by the non-parametric Mann-Whitney or, in case of matched samples by Wilcoxon tests. Comparison between three or more groups was performed by analysis of variance followed by multiple comparisons post-tests. A P-value o0.05 was considered significant.
RNA extraction and reverse transcriptase-PCR Total RNA was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. One microgram of RNA was retro-transcribed using SuperscriptIII (Invitrogen) with random examers. Quality of reverse transcriptase reactions was monitored by PCR amplification of the housekeeping gene glyceraldehyde-3 phosphate dehydrogenase using primers 5 0 -ACCATCTTCCC AGGAGCGAGAT-3 0 and 5 0 -GGCAGAGATGATGACCCT TT-3 0 , producing a 142 nucleotides fragment. After a denaturation at 94 1C for 2 min, 35 PCR cycles were performed (94 1C for 1 min, 54 1C for 1 min, 72 1C for 1 min), followed by a final extension at 72 1C for 2 min. For IGFBP7 amplification the following primers were used: 5 
IGFBP7 expression vector preparation
The IGFBP7 cDNA was obtained from HeLa cells by reverse transcriptase-PCR using the following primers: 5 0 -CCGGA ATTCCTGCCACCGCACCCCGCCAT-3 0 and 5 0 -GCCCAA GCTTTAGCTCGGCACCTTCACCTT-3 0 encompassing the IGFBP7 coding region and containing, respectively, the EcoRI and HindIII restriction sites (bold). The 923 nucleotides PCR product was digested with EcoRI and HindIII endonuclease and inserted into the pcDNA3.1/mycHis(À)A vector carrying compatible ends. The resulting construct encodes the IGFBP7-myc fusion protein.
Cell culture, transfection and treatments
The following thyroid tumor cells were used: TPC1, NIM1, BCPAP and K1, derived from PTC; BHT and KAT4, derived from anaplastic thyroid carcinoma; SK-MEL 31, derived from melanoma. All thyroid tumor cells were maintained at 37 1C, 5% CO 2 humidified atmosphere; K1 cell line was cultured in Dulbecco's modified Eagle's medium:HAM'S F12:MCDB 105 (2:1:1) with 2 mM glutamine and 10% fetal calf serum (FCS). All the other thyroid carcinoma cell lines were maintained in Dulbecco's modified Eagle's medium medium containing 10% FCS, 2 mM glutamine and 100U/ml penicillin/streptomycin. SK-MEL 31 cells were cultured in minimum essential medium Eagle's supplemented with 10% FCS at 37 1C, 10% CO 2 humidified atmosphere.
Transient and stable transfection of NIM1 cells was performed using Lipofectamine LTX (Invitrogen). Cells (4 Â 10 5 ) were seeded in 60 mm dishes, cultured for 24 h and transfected with 2 mg of plasmid DNA (pcDNA3.1/IGFBP7-myc or pCDNA3.1-myc, as control) and 5 ml of LTX, according to the manufacturer's instructions. After 48 h, transfected cells were either harvested and processed, or subjected to G418 (Life Technologies, Invitrogen, Carlsbad, CA, USA) selection (400 mg/ml). After 2 weeks of selection, G418-resistant colonies were either fixed and stained, or isolated and propagated in G418-containing medium.
For the 5-Aza-dC (Sigma Aldrich, St Louis, MO, USA) treatment, 6 Â 10 5 NIM1 cells were seeded in 100 mm dishes and treated with 5 mmol/l of 5-Aza-dC 24 h later. After 3 days of treatment, cells were harvested and processed for RNA isolation. For TRAIL (Genentech Inc., South San Francisco, CA, USA) treatment, 4 Â 10 5 cells were seeded in 60 mm dishes and exposed to 50 ng/ml TRAIL 24 h later. After 5 h of treatment, both attached and floating cells were collected and processed for protein extraction.
Immunodepletion of IGFBP7
CM from K1 cell line was collected and incubated with 2 mg/ml of IGFBP7 antibodies for 2 h at 4 1C with rotation. Afterward, 1 ml aliquot was incubated with 50 ml of protein A agarose beads (previously washed once with phosphate-buffered saline (PBS) and once with serum-free medium) for 24 h at 4 1C with rotation. After centrifugation, the supernatant was filtered through a 0.22 mM Millipore filter (Billerica, MA, USA) and added to the cells.
Growth curves
Growth curves were determined by alamarBlueAssay (Biosource, Nivelles, Belgium). Cells were plated in sextuple in 96-well multiwell (400 cells per well). After adhesion of cells, the alamarBlue reagent was added to the medium at 10% v/v. The fluorescence at l ¼ 590 and 535 nm was detected every 24 h from day 1 to day 5, using a microplate reader (TecanUltra Tecan Trading AG, Switzerland). Data were normalized for values detected at day 1.
Wound healing assay Cells (1.5 Â 10 6 ) were seeded into 60 mm dishes and incubated until they reached 80% confluency. A scratch was made through the center of the plate using a micropipette tip. Plates were washed with PBS, reefed with complete medium, and returned to the incubator. Images of the wound were collected at 0, 4, 8 and 24 h using a microscope magnification of Â 10 (LEICA, DMIRB). The migration rate was quantified by measuring the distance between the wound edges, and the percentage of migration was determined as ratio between migrated distance and scratched distance.
Soft agar assay Cells (5 Â 10 4 ) were suspended in 1.5 ml of Dulbecco's modified Eagle's medium containing 0.33% agar and 10% FCS, added into a layer of medium containing 0.5% agar and 10% FCS in 60 mm dishes, and incubated for 3 weeks. After staining with p-iodonitrotetrazolium chloride (Sigma Aldrich) the plates were analyzed for colony number and size.
Flow cytometry assay Cells were collected 3 days after transient transfection for DNA content analysis. Cells were washed twice with PBS and fixed for 24 h in cold ethanol (70%). After two washes with PBS, cells were incubated in PBS containing 1 mg/ml RNase and 50 mg/ml propidium iodide at room temperature for 30 min in the dark. Analysis was carried out using FACSCalibur (Becton Dickinson, San Jose, CA, USA) and data analysis was carried out using Cell Quest software (Becton Dickinson, San Jose, CA, USA).
Western blot analysis
Proteins were extracted in radioimmunoprecipitation assay modified buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% NonidetP-40) supplemented with Complete Mini EDTA-free protease Inhibitor Cocktail (Roche, Manheim, Germany), 1 mM Na 3 VO 4 and 1 mM PMSF. Protein samples were quantified by Bradford's assay with BIO-RAD Protein Assay (Bio-Rad, Munchen, Germany). CM, obtained by incubating cells in serum-free medium for 24 h, were concentrated by centrifugation at 4000 revolutions per minute using AgilentSpin Concentrators (Agilent Technologies Inc., Wilmington, DE, USA) and normalized to cell number. Protein and CM samples were boiled in NuPAGE LDS sample buffer (Invitrogen) and separated on 4-12% or 10% NuPAGE Novex Gel (Invitrogen) with MOPS or MES running buffer, respectively. Proteins were transferred onto nitrocellulose filters and immunoblotted with the appropriated antibodies: a-phospho-ERK, a-ERK and a-cleaved PARP (Cell Signaling Technology, Beverly MA, USA); a-p21 and a-IGFBP7 (Santa Cruz, Biotechnology, Inc. Santa Cruz, CA, USA); a-p53 (YLEM, Rome, Italy); a-b-actin and a-b-tubulin (Sigma Aldrich). The immunoreactive bands were visualized using horseradish peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence (GE, Bio-Rad, Hercules, CA, USA). The membranes were scanned using the Chemidoc XRS and densitometric analysis was performed by using Quantitative One software (Bio-Rad).
In vivo studies Animal studies were reviewed and approved by the ethics committee for animal experimentation of the Fondazione IRCCS 'Istituto Nazionale dei Tumori' and are in accordance with the guidelines of the UK Coordinating Committee for Cancer Research (UK Coordinating Committee on Cancer Research, 1988). Female CD-1 nu/nu mice (8-to 9-week old) (Charles River, Calco, Italy) were injected subcutaneously into the left flank with 2 Â 10 6 or 5 Â 10 6 cells in 0.2 ml PBS volume. Tumor growth was assessed by evaluating tumor latency, that is, days to reach 0.1 g, and by monitoring tumor weight twice a week. Tumor weight was estimated by the formula TW(g) ¼ d2 Â D/2 where d and D are the shortest and the longest diameters of the tumor, respectively, measured in cm.
